BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology (NASDAQ:CLVS) today announced preliminary Phase 2 results from the ARIEL2 (Assessment of Rucaparib In Ovarian Cancer Trial) study and updated results from the ongoing Phase 1/2 monotherapy study of rucaparib. Rucaparib is the Company’s investigational oral, potent, small molecule inhibitor of PARP1 and PARP2 being developed for the treatment of platinum-sensitive ovarian cancer in patients with homologous recombination deficient (HRD) tumors, defined as those with BRCA mutations and other DNA repair deficiencies. These data are being presented today at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid.
Help employers find you! Check out all the jobs and post your resume.
